Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labo Euromedis's EBIT per Share for the
six
months ended in Dec. 2025 was €0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.32.
During the past 12 months, the average EBIT per Share Growth Rate of Labo Euromedis was -52.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Labo Euromedis's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Labo Euromedis was 163.50% per year. The lowest was -28.20% per year. And the median was -5.60% per year.
FRA:61R's 3-Year EBIT Growth Rate is not ranked *
in the Medical Distribution industry.
Industry Median: 4.2 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Labo Euromedis's EBIT for the
six
months ended in Dec. 2025 was €0.64 Mil.
Labo Euromedis (FRA:61R) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Labo Euromedis EBIT per Share Related Terms
Labo Euromedis EBIT per Share Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (FRA:61R) has a EBIT per Share of €0.32 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Labo Euromedis and its competitors. According to the industry distribution chart, Labo Euromedis ranks #999999 out of 105 companies in the Medical Distribution industry.
Is Labo Euromedis' EBIT per Share too high?
Labo Euromedis' current EBIT per Share is €0.32. Based on the distribution chart, Labo Euromedis ranks #999999 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Labo Euromedis has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' EBIT per Share compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #999999 out of 105 companies for EBIT per Share. This places Labo Euromedis in the lower half of its industry. The industry median EBIT per Share is 4.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.20, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current EBIT per Share is €0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current EBIT per Share of €0.32. The stock's GF Value™ is €4.35, compared to a current price of €4.78 — trading 9.9% above its estimated fair value. The current EBIT per Share is €0.32. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current EBIT per Share is €0.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.78 is trading 9.9% above its estimated GF Value™ of €4.35.
Key valuation signals for FRA:61R:
EBIT per Share: €0.32
GF Value™: €4.35 vs. price of €4.78 (9.9% above fair value)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score
Get the complete analysis for FRA:61R
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
